Last updated: September 7, 2026
Asimadoline is an investigational oral, selective kappa-opioid receptor agonist that reached mid- to late-stage development for irritable bowel syndrome with diarrhea (IBS-D). Its development was not converted into an FDA-approved product. Public evidence indicates that asimadoline has no current marketed product, no FDA approval, no active Orange Book-listed reference product, and no meaningful near-term commercial revenue opportunity. Its residual value is limited to potential asset redevelopment, licensing, or use as a pharmacological reference compound.
What is the current development status of asimadoline?
Asimadoline is not an approved medicine and does not have an active commercial development program publicly identified in major clinical registries.
| Field |
Status |
| Active ingredient |
Asimadoline |
| Development code |
EMD 61753 |
| Drug class |
Selective kappa-opioid receptor agonist |
| Route |
Oral |
| Primary historical indication |
IBS-D |
| Other investigated uses |
Functional gastrointestinal disorders, visceral pain, pruritus and addiction-related conditions |
| FDA approval |
None identified |
| FDA regulatory filing |
No public NDA approval identified |
| Marketing authorization |
None identified |
| Current commercial product |
None |
| Development status |
Discontinued or inactive in public records |
| Biosimilar relevance |
None; asimadoline is a small molecule |
| Generic competition |
No commercial generic market identified |
Asimadoline was designed to activate peripheral and central kappa-opioid receptors while limiting the abuse liability associated with mu-opioid agonists. The program focused on reducing visceral pain, urgency and diarrhea without producing the degree of euphoria, respiratory depression or constipation associated with conventional opioid therapy.
The most advanced development centered on IBS-D. Clinical results showed activity in selected patient groups, particularly patients with more severe diarrhea and abdominal pain, but the program did not produce a reliable efficacy profile across the broader target population.
What clinical trials evaluated asimadoline?
Asimadoline was evaluated in multiple early and mid-stage clinical studies, with the largest development emphasis placed on gastrointestinal disorders.
IBS-D development
The historical IBS-D program evaluated oral asimadoline in patients with diarrhea-predominant disease. Reported endpoints included:
- Abdominal pain intensity
- Stool frequency
- Stool consistency
- Urgency
- Global symptom relief
- Responder rates based on composite IBS criteria
The drug showed signals of benefit in some subgroup analyses. The most consistent historical signal was in patients with severe diarrhea or more pronounced gastrointestinal symptoms. The overall development problem was that subgroup activity did not translate into a sufficiently robust and reproducible efficacy result for broad registration.
Clinical development in IBS-D was therefore vulnerable to:
- High placebo response rates.
- Heterogeneous diagnostic criteria.
- Variable definitions of treatment response.
- Weak differentiation from symptomatic therapies.
- Difficulty translating receptor-level activity into durable global symptom improvement.
Other clinical research
Asimadoline was also studied or considered for conditions involving visceral hypersensitivity, opioid-sensitive pain pathways and pruritus. These programs did not produce an approved indication.
Historical research areas included:
| Disease area |
Development rationale |
Outcome |
| IBS-D |
Reduce visceral pain, urgency and diarrhea |
No approved product |
| Functional gastrointestinal disorders |
Modulate visceral hypersensitivity |
No commercial launch |
| Cholestatic or opioid-related pruritus |
Kappa-receptor activity may reduce itch |
No approved asimadoline product |
| Substance-use disorders |
Explore kappa-mediated effects on reward and craving |
No approved product |
| Visceral pain |
Reduce nociceptive signaling without conventional opioid liabilities |
No commercial launch |
ClinicalTrials.gov and PubChem identify asimadoline as an investigational compound rather than an active marketed therapy (U.S. National Library of Medicine, n.d.; National Center for Biotechnology Information, n.d.).
When did asimadoline development lose momentum?
The program lost commercial momentum after late-stage IBS-D development failed to establish a sufficiently broad and reproducible treatment effect.
A simplified development timeline is:
| Period |
Development event |
| 1990s |
Preclinical and early clinical investigation of selective kappa-opioid activity |
| Early 2000s |
Human studies in visceral pain and gastrointestinal disorders |
| Mid-2000s |
Continued evaluation in IBS-D and related conditions |
| Late 2000s |
Mid-stage IBS-D data suggested possible benefit in selected severe-symptom patients |
| Early 2010s |
Late-stage development failed to generate a registration-ready profile |
| After early 2010s |
No public FDA approval, commercial launch or sustained pivotal program |
The asset appears to have become inactive because efficacy was not sufficiently predictable across the intended IBS-D population. That outcome reduced the likelihood that a sponsor would fund a new registration program without a narrower biomarker-defined population, a redesigned endpoint strategy or a new formulation.
What is the FDA regulatory status of asimadoline?
Asimadoline has no identified FDA approval and no publicly established FDA-approved label.
The FDA Orange Book is intended to identify approved drug products and related patent and exclusivity information. A search for asimadoline does not establish an approved reference listed drug or a commercial Orange Book product (U.S. Food and Drug Administration, n.d.-a).
| FDA issue |
Asimadoline status |
| Approved active ingredient |
No |
| Approved dosage form |
No |
| NDA approval |
No public approval identified |
| ANDA generic pathway |
Not commercially active |
| Orange Book patents |
No active approved-product listing identified |
| NCE exclusivity |
No current relevance |
| Pediatric exclusivity |
None identified |
| Orphan exclusivity |
None identified |
| Paragraph IV litigation |
No meaningful commercial Paragraph IV record identified |
Because asimadoline never reached an approved reference-product position, the conventional Hatch-Waxman lifecycle framework does not currently create a meaningful generic-entry event. The principal regulatory issue is development risk, not generic erosion.
What patents protect asimadoline?
The historical patent position is difficult to translate into current commercial protection because the compound was discovered decades ago and no approved product appears to be marketed.
Publicly available records indicate that historical protection likely covered one or more of the following:
- The asimadoline chemical entity.
- Related kappa-opioid agonist compounds.
- Pharmaceutical compositions.
- Treatment of visceral pain or gastrointestinal disorders.
- Dosing or use in IBS-D.
- Processes for preparing the compound or intermediates.
A definitive current patent-expiration analysis requires patent-family review by jurisdiction and claim scope. The public commercial record does not establish an active, enforceable product-level estate that would block a new sponsor from developing asimadoline today.
Patent-estate assessment
| Patent category |
Current commercial relevance |
| Composition-of-matter patents |
Likely historical; probable expiration risk because of early priority dates |
| Formulation patents |
No clearly identified active commercial formulation estate |
| Method-of-use patents |
Possible historical protection for IBS-D or visceral pain; limited current value without approval |
| Manufacturing patents |
May protect specific processes but are unlikely to create a broad market barrier |
| Orange Book-listed patents |
None identified for an approved product |
| Regulatory exclusivity |
None currently available |
| Freedom-to-operate risk |
Requires jurisdiction-specific review, but appears lower than for a recently discovered compound |
What formulations are protected by asimadoline patents?
No current commercial formulation has been identified. Historical development used oral dosage forms, but the public record does not establish a marketed extended-release tablet, capsule, combination product or other proprietary delivery system.
A new sponsor could face patent questions involving:
- Salt or polymorph selection.
- Particle size and solid-state form.
- Oral bioavailability.
- Modified-release delivery.
- Combination therapy with antidiarrheal or neuromodulatory agents.
- Patient-selection methods for severe IBS-D.
Those issues would matter only if a sponsor resumed development and generated new patentable subject matter. They do not create an established current formulation moat.
Does asimadoline have method-of-use patent protection?
Historical method-of-use claims may have covered treatment of gastrointestinal pain, diarrhea, IBS or visceral hypersensitivity. Their present value is constrained by three factors:
- The likely age of the underlying filings.
- The absence of an approved commercial product.
- The ability of a future sponsor to pursue a different indication, patient population, dose or treatment regimen.
A future program could seek new use patents for a biomarker-defined subgroup, such as patients with severe diarrhea, high visceral pain sensitivity or a specific receptor-expression profile. Such patents would be narrower than a broad IBS-D claim and would require clinical support.
What is the patent strength of asimadoline?
The current patent estate appears weak from a commercial-product perspective.
| Patent-strength factor |
Assessment |
| Composition protection |
Likely weakened by age and expiration |
| Regulatory exclusivity |
None |
| Orange Book leverage |
None identified |
| Formulation differentiation |
Limited public evidence |
| Method-of-use protection |
Potentially narrow and historically focused |
| Manufacturing barrier |
Possible but unlikely to prevent alternative synthesis |
| Litigation leverage |
Low without an approved product or active commercial launch |
| Repositioning potential |
Moderate if a new clinical niche is validated |
The asset’s main barrier is clinical validation, not a strong blocking patent estate.
Which companies developed or challenged asimadoline?
Asimadoline was historically associated with Merck-related development activity and later with biotechnology-led development efforts involving Tioga Pharmaceuticals. Public records do not indicate an active current sponsor pursuing FDA approval.
No significant current competitor is challenging an approved asimadoline product because no such product exists. The competitive challenge comes from established IBS-D therapies and newer gut-brain or symptom-directed approaches.
Relevant competitors include:
| Therapy |
Company or originator |
IBS-D position |
| Xifaxan (rifaximin) |
Salix Pharmaceuticals, now part of Bausch Health |
Approved for IBS-D |
| Viberzi (eluxadoline) |
Allergan/AbbVie |
Approved for IBS-D; commercial status has changed over time |
| Lotronex (alosetron) |
Various commercial holders |
Restricted use in severe IBS-D |
| Loperamide |
Multiple generic manufacturers |
Symptomatic diarrhea control |
| Tricyclic antidepressants |
Multiple manufacturers |
Off-label visceral pain and symptom management |
| Linaclotide and plecanatide |
AbbVie/Ironwood and Synergy/Salix |
Primarily IBS-C, not direct IBS-D competitors |
| Tenapanor |
Ardelyx |
Primarily IBS-C |
Asimadoline would need to demonstrate a clinically meaningful advantage over rifaximin, eluxadoline, alosetron and low-cost symptomatic treatment. A receptor-specific mechanism alone would not establish commercial differentiation.
What is the commercial market projection for asimadoline?
The base-case forecast is zero approved-product revenue in the near term because no active registration program or commercial launch is publicly established.
A scenario-based projection is more appropriate than a conventional sales forecast.
| Scenario |
Probability characterization |
Commercial outcome |
| Base case |
Most likely absent a new sponsor |
No commercial revenue |
| Repositioning case |
Requires new clinical evidence and sponsor funding |
Limited specialty launch, likely several years away |
| Positive subgroup case |
Requires validated severe-IBS-D or biomarker-defined population |
Niche product with moderate pricing potential |
| Broad IBS-D success case |
Requires replicated pivotal efficacy and safety |
Material commercial opportunity, but low probability based on historical development |
| Licensing-only case |
Asset transferred for research or redevelopment |
Upfront or milestone value rather than product sales |
Addressable market
IBS-D is a large diagnosed and undiagnosed population, but the commercial opportunity for a new therapy depends on the treated severe-symptom segment. Existing therapies have already established treatment pathways, and payers generally require evidence of durable symptom improvement.
A successfully redeveloped asimadoline could target:
- Patients with severe diarrhea.
- Patients with abdominal pain and urgency inadequately controlled by rifaximin or loperamide.
- Patients who cannot use eluxadoline because of gallbladder, pancreatitis or alcohol-related restrictions.
- Patients requiring a non-mu-opioid mechanism.
- Patients selected through a visceral hypersensitivity or receptor-response biomarker.
The commercial ceiling would be lower than the total IBS-D population unless clinical development demonstrates broad efficacy. A niche, second-line product could support specialty pricing, but the drug would face generic and low-cost alternatives.
What generic launch risks exist for asimadoline?
There is no current generic launch event because there is no approved reference product.
If asimadoline were redeveloped and approved, generic risk would depend on the new sponsor’s ability to obtain:
- Composition or solid-form patents.
- Formulation patents.
- Method-of-use claims.
- Regulatory exclusivity.
- Commercially meaningful differentiation.
Because the underlying molecule is old, a future sponsor would likely rely on formulation, use, dosing or patient-selection patents rather than long-lived composition-of-matter protection. That structure would make the product vulnerable to patent challenges after launch, particularly if the label contains broad IBS-D claims.
What litigation and settlement agreements affect asimadoline?
No major active patent litigation or settlement agreement involving an approved asimadoline product is identified in the public record.
The absence of litigation is consistent with the compound’s development status. Patent litigation generally becomes commercially significant after:
- FDA approval.
- Orange Book listing.
- Abbreviated new drug application filing.
- Commercial generic launch.
- A dispute over a marketed formulation or use.
Asimadoline has not reached those milestones.
How does asimadoline compare with approved IBS-D drugs?
| Attribute |
Asimadoline |
Rifaximin |
Eluxadoline |
Alosetron |
| Approval status |
Investigational |
FDA approved for IBS-D |
FDA approved for IBS-D |
FDA approved with restrictions |
| Mechanism |
Selective kappa-opioid agonist |
Gut-directed antibacterial |
Mixed opioid receptor activity |
5-HT3 antagonist |
| Main target |
Visceral pain, urgency, diarrhea |
Global IBS-D symptoms |
Diarrhea and abdominal pain |
Severe IBS-D, mainly women |
| Abuse liability |
Designed to be lower than mu-opioids |
None typical of opioids |
Opioid-related restrictions |
Non-opioid |
| Current patent leverage |
None identified for an approved product |
Product and use protection historically relevant |
Product and use protection historically relevant |
Historical product and use protection |
| Commercial status |
No launch |
Established |
Established or commercially variable |
Restricted niche |
| Development risk |
High, because efficacy was not registration-ready |
Low as an approved therapy |
Regulatory and safety restrictions |
Safety and prescribing restrictions |
Asimadoline’s theoretical advantage is its selective kappa mechanism and potential for treating pain and diarrhea without conventional mu-opioid effects. Its practical disadvantage is the absence of a successful pivotal development package.
What would be required to revive asimadoline?
A credible redevelopment plan would require:
- A new sponsor with rights to the compound and relevant intellectual property.
- A defined target population rather than an undifferentiated IBS-D population.
- Reproducible evidence in patients with severe diarrhea, urgency and abdominal pain.
- A modern endpoint strategy aligned with FDA IBS-D guidance.
- Updated safety data, including psychiatric, neurologic and opioid-class effects.
- A commercial formulation with defensible intellectual property.
- A comparative strategy against rifaximin, eluxadoline and standard symptomatic treatment.
- A regulatory interaction with the FDA before pivotal redevelopment.
The most credible path would be a narrow, biomarker-supported or high-severity indication. A broad IBS-D program would face substantial historical and competitive risk.
Key Takeaways
- Asimadoline is an investigational selective kappa-opioid agonist, not an approved drug.
- Its principal historical indication was IBS-D.
- The program did not produce an FDA-approved product or commercial launch.
- No active Orange Book reference product, meaningful Paragraph IV campaign or major current litigation has been identified.
- The historical composition-of-matter estate is likely weakened by age; current commercial value would depend on new formulation, dosing or method-of-use patents.
- The near-term revenue forecast is effectively zero under the base case.
- Any commercial recovery would require a new sponsor, new clinical evidence and a narrower target population.
- Competition from rifaximin, eluxadoline, alosetron, loperamide and off-label therapies would limit market penetration.
- The main risk is clinical and regulatory feasibility, not generic erosion of an existing product.
FAQs About Asimadoline
Is asimadoline approved by the FDA?
No. Asimadoline has not received FDA approval and is not marketed as an approved prescription drug.
Is asimadoline an opioid?
Asimadoline is a kappa-opioid receptor agonist. It was designed to produce therapeutic receptor activity without the full profile of conventional mu-opioid drugs.
Can asimadoline be prescribed for IBS-D?
No approved prescription pathway exists for asimadoline. Its use remains investigational.
Does asimadoline have biosimilar competition?
No. Biosimilars apply to biologic products. Asimadoline is a small molecule and has no marketed generic competition because it was never approved as a commercial reference drug.
Could asimadoline be relicensed for a new indication?
Yes, in principle. The most plausible redevelopment strategy would involve a new clinical population, formulation or treatment method. The commercial case would depend on obtaining new clinical and intellectual-property protection.
References
-
National Center for Biotechnology Information. (n.d.). Asimadoline. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. National Library of Medicine. (n.d.). Asimadoline clinical studies. ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2012). Guidance for industry: Irritable bowel syndrome with diarrhea: Developing drugs for treatment. https://www.fda.gov/
-
Holzer, P. (2004). Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 19(5), 547-556.
-
Holzer, P. (2011). Opioid receptors in the gastrointestinal tract. Regulatory Peptides, 169(1-3), 30-41.
